HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Aryl hydrocarbon receptor-microRNA-212/132 axis in human breast cancer suppresses metastasis by targeting SOX4.

AbstractBACKGROUND:
MicroRNAs (miRNAs) are a class of short non-coding RNAs that pave a new avenue for understanding immune responses and cancer progression. Although the miRNAs are involved in breast cancer development, their axis with the transcription factors that show therapeutic potential in breast cancer is largely unknown. Previous studies showed anti-metastatic roles of agonist-activated aryl hydrocarbon receptor (Ahr) in various breast cancer cell lines. Recently, we demonstrated that agonist-activated Ahr induced a highly conserved miRNA cluster, named miR-212/132, in murine cellular immune compartment. Therefore, current study was performed to examine if this miRNA cluster mediates the anti-metastatic properties of Ahr agonists.
METHODS:
The expression of miR-212/132 cluster and coding genes were examined by real-time PCR, and the protein levels were detected by western blot. The 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and 3,3'-diindolylmethane (DIM) were used to activate Ahr in MDA-MB-231 and T47D breast cancer cells. Chromatin immunoprecipitation (ChIP) assay was used to identify the binding site(s) for Ahr on miR-212/132 promoter. For prediction of potentially target gene of the miRNA cluster, bioinformatics analysis was carried out, and to test targeting, luciferase activity was quantified. Besides, biological effects of Ahr-miR-212/132 axis were examined in vitro by cell migration, expansion and invasion, and examined in vivo by orthotopic model of spontaneous metastasis.
RESULTS:
The miR-212/132 cluster was transcriptionally activated in MDA-MB-231 and T47D cells by TCDD and DIM, and this activation was regulated by Ahr. A reciprocal correlation was identified between Ahr agonists-induced miR-212/132 and the pro-metastatic SRY-related HMG-box4 (SOX4), and a new specific binding sites for miR-212/132 were identified on the untranslated region (3'UTR) of SOX4. Interestingly, miR-212/132 over-expression showed direct anti-migration, anti-expansion and anti-invasion properties, and an inhibition of the miRNA cluster mitigated the anti-invasive properties of TCDD and DIM. Further in vivo studies demonstrated that the Ahr-miR-212/132-SOX4 module was induced by Ahr activation.
CONCLUSION:
Taken together, the findings provide the first evidences of the synergistic anti-metastatic properties of miR-212/132 cluster through suppression of SOX4. Also, current study suggest a new miRNA-based mechanism elucidating the anti-metastatic properties of Ahr agonists, suggesting possibility of using miR-212/132 to control metastasis in breast cancer patients.
AuthorsHamza Hanieh
JournalMolecular cancer (Mol Cancer) Vol. 14 Pg. 172 (Sep 17 2015) ISSN: 1476-4598 [Electronic] England
PMID26377202 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • 1,1-bis(3'-indolyl)methane
  • 3' Untranslated Regions
  • Indoles
  • MIRN132 microRNA, human
  • MIRN212 microRNA, human
  • MicroRNAs
  • Polychlorinated Dibenzodioxins
  • Receptors, Aryl Hydrocarbon
  • SOX4 protein, human
  • SOXC Transcription Factors
Topics
  • 3' Untranslated Regions
  • Animals
  • Binding Sites (drug effects)
  • Breast Neoplasms (genetics, pathology)
  • Cell Movement (genetics)
  • Female
  • Gene Expression Regulation, Neoplastic (drug effects)
  • Humans
  • Indoles (administration & dosage)
  • Mice
  • MicroRNAs (biosynthesis, genetics)
  • Neoplasm Metastasis
  • Polychlorinated Dibenzodioxins (administration & dosage)
  • Receptors, Aryl Hydrocarbon (biosynthesis, genetics)
  • SOXC Transcription Factors (genetics)
  • Signal Transduction (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: